-
公开(公告)号：US11344519B2
公开(公告)日：2022-05-31
申请号：US17132765
申请日：2020-12-23
发明人： Anke Stroyer , Carmen Lobback , Peter Serno , Philipp Rubenbauer , Kai Lovis , Heiko Schirmer , Danja Grossbach , Donald Bierer , Britta Olenik , Tia Jacobs , Julia Küsel
IPC分类号： A61K31/00 , A61K9/00 , A61K31/192 , A61K9/20 , A61K47/10 , A61K47/38 , A61K45/06 , A61P25/28 , A61P13/00 , A61P9/10
摘要： The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
-
公开(公告)号：US10905667B2
公开(公告)日：2021-02-02
申请号：US16043567
申请日：2018-07-24
发明人： Anke Stroyer , Carmen Lobback , Peter Serno , Philipp Rubenbauer , Kai Lovis , Heiko Schirmer , Danja Grossbach , Donald Bierer , Britta Olenik , Tia Jacobs , Julia Küsel
IPC分类号： A61K31/00 , A61K9/00 , A61K47/00 , A61P9/10 , A61P25/28 , A61K31/192 , A61K9/20 , A61K47/10 , A61K47/38 , A61K45/06 , A61P13/00
摘要： The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
-
公开(公告)号：US20200030270A1
公开(公告)日：2020-01-30
申请号：US16043567
申请日：2018-07-24
发明人： Anke Stroyer , Carmen Lobback , Peter Serno , Philipp Rubenbauer , Kai Lovis , Heiko Schirmer , Danja Grossbach , Donald Bierer , Britta Olenik , Tia Jacobs , Julia Kusel
摘要： The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
-
公开(公告)号：US20220257547A1
公开(公告)日：2022-08-18
申请号：US17732761
申请日：2022-04-29
发明人： Anke Stroyer , Carmen Lobback , Peter Serno , Philipp Rubenbauer , Kai Lovis , Heiko Schirmer , Danja Grossbach , Donald Bierer , Britta Olenik , Tia Jacobs , Julia Küsel
摘要： The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
-
公开(公告)号：US20210113504A1
公开(公告)日：2021-04-22
申请号：US17132765
申请日：2020-12-23
发明人： Anke Stroyer , Carmen Lobback , Peter Serno , Philipp Rubenbauer , Kai Lovis , Heiko Schirmer , Danja Grossbach , Donald Bierer , Britta Olenik , Tia Jacobs , Julia Küsel
摘要： The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
-
-
-
-
搜索结果
5 条记录 (耗时 0.019 秒)
